-
PDF
- Split View
-
Views
-
Cite
Cite
M Mihalovic, P Mikulenka, H Linkova, I Stetkarova, T Peisker, P Tousek, Elevated GDF-15 is associated with stroke severity, myocardial injury and poor clinical outcome in patients after acute ischemic stroke, European Heart Journal, Volume 45, Issue Supplement_1, October 2024, ehae666.2316, https://doi.org/10.1093/eurheartj/ehae666.2316
- Share Icon Share
Abstract
GDF-15 is emerging as a biomarker of cardiometabolic risk and disease burden. Increased concentrations of circulating GDF-15 are associated with increased mortality in patients with acute coronary syndromes or heart failure.
We aimed to describe relation between GDF-15 elevation with stroke severity, myocardial injury and poor clinical outcome in patients after acute ischemic stroke (AIS).
Patients after AIS were enrolled in our study. Blood samples were obtained from patients at the time of admission, 24 and 48 hours later to determine the plasma levels of GDF-15 and high-sensitive troponin I (hs-cTnI). Receiver-operating characteristic (ROC) curve analysis was used to determine the diagnostic accuracy and optimal elevation cut-off values of GDF-15 on day 1 for the severity of acute stroke defined by NIHSS score. The optimal cut off in our group was 1776 pg/ml (Sensitivity 0,8, Specificity 0,52). Myocardial injury was defined by fourth universal definition of myocardial infarction using hs-cTnI. Demographic characteristics, clinical data, functional outcome, and all-cause mortality at 1 year were compared between groups according to GDF-15 levels. National Institutes of Health Stroke Scale (NIHSS) at the time of admission and the modified Rankin Scale (mRS) 90 days following the patient’s discharge from the hospital were used to assess stroke severity and clinical outcome. All analyses were performed with SPSS 29.0 (SPSS Inc).
Between August 2020 and August 2022, 177 patients after AIS were enrolled. Elevated GDF-15 was observed in 71 patients (40,1%). Most common comorbidities included arterial hypertension, dyslipidemia, type 2 DM and atrial fibrillation. In analysis, we observed a connection between elevated GDF-15 with unfavourable outcome evaluated by mRS at 90 days (HR 2.57, 95% CI 1,44 to 4,57, p=0.001) and with all-cause death at 1 year (HR 4.479, 95% CI 1,81 to 11,09, p=0.001). GDF-15 elevation was associated with myocardial injury (Figure 1C). Moreover, individuals with moderate to severe and severe strokes (NIHSS 16-42) displayed higher GDF-15 levels compared to those with minor to moderate stroke (Figure 1D). The Kaplan-Meier survival curve accentuated a significantly elevated all-cause mortality among patients with increased GDF-15 (p < 0.001) (Figure 2). In multivariate regression analysis elevated GDF-15 was associated with atrial fibrillation and high-sensitive troponin I elevation.
Author notes
Funding Acknowledgements: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Supported by Charles University Research Program Cooperatio–Cardiovascular sciences, UNCE-MED.
- acute cerebrovascular accidents
- acute coronary syndromes
- atrial fibrillation
- dyslipidemias
- myocardial infarction
- hypertension
- cerebrovascular accident
- ischemic stroke
- heart failure
- diabetes mellitus, type 2
- biological markers
- comorbidity
- cost of illness
- demography
- plasma
- diagnosis
- mortality
- treatment outcome
- troponin i
- myocardial injury
- kaplan-meier survival curve
- nih stroke scale
- cardiac troponin i
- rankin scale
- growth differentiation factor 15
- cardiometabolic risk factors